(MENAFN- Straits Research)
Anti-VEGF Therapeutics Market Size & Growth Analysis
The global anti-vegf therapeutics market size was valued at USD 14.8 billion in 2025 and is projected to grow from USD 15.14 billion in 2026 to USD 18.19 billion by 2034, registering a CAGR of 2.32% during the forecast period from 2026 to 2034. North America dominated the anti-vegf therapeutics market with a market share of 42.5% in 2025.
Anti-VEGF therapeutics are medicines designed to block vascular endothelial growth factor (VEGF), a protein that promotes the formation and growth of blood vessels. They are widely used to treat conditions such as cancer and retinal diseases by limiting abnormal blood vessel growth. Demand is growing due to increasing cases of cancer and vision disorders, advances in targeted therapies, and rising adoption of biologic treatments.
Anti-VEGF Therapeutics Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 14.8 Billion
2026 Market Size: USD 15.14 Billion
2034 Projected Market Size: USD 18.19 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 2.32%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 42.5%
Fastest-Growing Region: Asia-Pacific
Asia-Pacific CAGR (2026–2034): 9.4%
Segment Insights
By Product
Leading Segment: Eylea
Market Share in 2025: 39.8%
By Product
Fastest-Growing Segment: Vabysmo
CAGR: 13.2% (2026–2034)
By Disease Type
Leading Segment: Age-related Macular Degeneration
Market Share in 2025: 38.7%
By Disease Type
Fastest-Growing Segment: Diabetic Retinopathy
CAGR: 9.1% (2026–2034)
Download a Free Sample To learn more about this report,
Anti-VEGF Therapeutics Market Trends
Growing Adoption of Anti-VEGF Therapies for Retinal Disorders
anti-vegf therapeutics market trends are being driven by the increasing use of vascular endothelial growth factor inhibitors for treating retinal conditions such as age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Anti-VEGF therapies can help reduce abnormal blood vessel growth and fluid accumulation in the retina, supporting vision preservation in eligible patients. Rising prevalence of diabetes and age-related eye diseases is increasing demand for effective retinal treatments. These developments are supporting anti-vegf therapeutics market growth as ophthalmology continues to adopt targeted biologic therapies.
In February 2025, Roche continued expanding access to Vabysmo (faricimab), an anti-VEGF therapy used for several retinal conditions, supporting the broader adoption of longer-acting treatment approaches.
Rising Shift Toward Longer-Acting and Less Frequent Treatments
Drug developers are increasingly focusing on anti-VEGF therapies that can maintain treatment effectiveness for longer periods and potentially reduce the frequency of intravitreal injections. Longer dosing intervals can help address treatment burden and improve patient convenience, particularly for chronic retinal diseases requiring repeated therapy. Pharmaceutical companies are also developing novel formulations and delivery approaches to extend drug durability within the eye. These innovations are strengthening anti-vegf therapeutics market share by increasing demand for therapies that combine effective disease control with more convenient treatment schedules.
In May 2025, Regeneron continued advancing EYLEA HD (aflibercept) as a higher-dose anti-VEGF treatment option designed to provide extended dosing intervals for patients with certain retinal diseases.
Anti-VEGF Therapeutics Market Dynamics
Market Drivers
Growing Prevalence of Retinal and Cancer-Related Disorders
The anti-VEGF therapeutics market is growing steadily as healthcare providers increasingly use vascular endothelial growth factor inhibitors to manage diseases associated with abnormal blood vessel growth. These therapies are widely used in ophthalmology for conditions such as wet age-related macular degeneration and diabetic macular edema, while VEGF-targeting approaches also have important applications in oncology. Rising disease prevalence and advances in targeted therapies are strengthening anti-VEGF therapeutics market demand globally.
In February 2025, pharmaceutical companies expanded anti-VEGF treatment options and clinical development programs to improve disease management and provide more therapeutic choices for patients with VEGF-related disorders.
Market Restraints
High Treatment Costs and Frequent Administration Requirements
The anti-VEGF therapeutics market faces restraints because many treatments require repeated administration and long-term monitoring, particularly in retinal diseases. The cost of biologic therapies, specialist consultations, and repeated clinical visits can create financial pressure for patients and healthcare systems. Limited access to specialized ophthalmic and oncology services can further restrict treatment availability in some regions.
During April 2025, healthcare providers and pharmaceutical companies increased efforts to improve treatment affordability and delivery efficiency to reduce the burden associated with repeated anti-VEGF therapy.
Market Opportunities
Development of Longer-Acting and Next-Generation Anti-VEGF Therapies
The anti-VEGF therapeutics market offers strong opportunities as pharmaceutical companies develop longer-acting formulations, sustained-release delivery systems, and therapies with improved durability. These approaches can potentially reduce injection frequency and improve treatment adherence. Increasing investment in targeted biologics and innovative drug-delivery technologies is expected to strengthen anti-VEGF therapeutics market share over the coming years.
In July 2025, pharmaceutical developers expanded research into extended-duration anti-VEGF formulations and advanced drug-delivery approaches aimed at reducing treatment frequency and improving convenience for patients requiring long-term therapy.
Market Challenges
Managing Treatment Resistance and Long-Term Patient Adherence
The anti-VEGF therapeutics market continues to face challenges related to variable treatment responses, disease progression, and the need for repeated administration. Some patients may develop inadequate responses or require treatment adjustments over time. Maintaining regular follow-up and treatment adherence can also be difficult, particularly for patients requiring long-term ophthalmic therapy.
By October 2025, researchers and pharmaceutical companies increased clinical evaluation of combination and next-generation anti-VEGF approaches to address incomplete treatment responses, improve durability, and support more consistent long-term disease management.
Anti-VEGF Therapeutics Market Segmentation Analysis
By Product
Eylea Segment Dominated the Market with 39.8% Share in 2025
The Eylea segment dominated the global anti-VEGF therapeutics market with a 39.8% share in 2025. Eylea is widely used for the treatment of several retinal disorders, including age-related macular degeneration and diabetic eye diseases. Its established clinical use and broad therapeutic applications continue to support the segment's leading position.
Lucentis accounted for 23.4% of the market, followed by Vabysmo with 17.6%. Beovu represented 8.7%, while other products accounted for 10.5%. Vabysmo is growing at the highest CAGR of 13.2%, supported by increasing adoption of newer anti-VEGF treatment options and demand for advanced therapies. These developments are supporting anti-VEGF therapeutics market growth.
Request Customization to receive a tailored report.
By Disease Type
Age-related Macular Degeneration Segment Dominated the Market with 38.7% Share in 2025
The age-related macular degeneration segment dominated the global anti-VEGF therapeutics market with a 38.7% share in 2025. Age-related macular degeneration is a major retinal condition requiring ongoing treatment, creating substantial demand for anti-VEGF therapies. The large patient population and continued need for disease management support the segment's leading position.
Macular edema accounted for 22.6% of the market, followed by diabetic retinopathy at 19.4% and retinal vein occlusion at 14.8%. Diabetic retinopathy is growing at the highest CAGR of 9.1%, driven by the increasing prevalence of diabetes and the resulting risk of retinal complications. Myopic choroidal neovascularization accounted for 4.5% of the market, while continued advances in retinal disease treatment are supporting overall anti-VEGF therapeutics market demand.
Speak to an Analyst to discuss market opportunities.
Anti-VEGF Therapeutics market Regional Outlook
North America Anti-VEGF Therapeutics market Analysis
North America dominated the anti-VEGF therapeutics market with a 42.5% share in 2025, valued at USD 6.29 billion, and is projected to grow at a CAGR of 7.2% during the forecast period. The region's advanced healthcare infrastructure, high prevalence of retinal disorders and cancer, strong adoption of biologic therapies, and significant healthcare expenditure are supporting market growth. Increasing demand for targeted therapies, expanding ophthalmology applications, and continued research and development in anti-VEGF treatments are further contributing to regional expansion.
United States anti-VEGF therapeutics market Insights
The United States market was valued at approximately USD 5.35 billion in 2025, making it the largest contributor to the North American market. High healthcare expenditure, advanced ophthalmic care infrastructure, increasing prevalence of age-related macular degeneration and diabetic retinopathy, and widespread adoption of anti-VEGF therapies are supporting market development.
Canada anti-VEGF therapeutics market Insights
The Canada market reached approximately USD 0.94 billion in 2025. Increasing prevalence of retinal diseases, improving access to advanced ophthalmic treatments, rising healthcare expenditure, and growing adoption of biologic therapies are supporting the demand for anti-VEGF therapeutics.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Anti-VEGF Therapeutics market Analysis
Europe accounted for 27.3% of the global anti-VEGF therapeutics market in 2025, reaching USD 4.04 billion, and is expected to grow at a CAGR of 6.8% during the forecast period. Growing prevalence of ophthalmic disorders, increasing geriatric populations, established healthcare systems, and rising adoption of advanced biologic therapies are driving regional demand. Improvements in diagnosis and treatment of retinal diseases are also supporting the use of anti-VEGF therapeutics.
Germany anti-VEGF therapeutics market Insights
Germany's market accounted for approximately USD 1.15 billion in 2025. A well-developed healthcare infrastructure, increasing prevalence of age-related retinal disorders, strong adoption of advanced ophthalmic therapies, and growing demand for effective biologic treatments are supporting market growth.
United Kingdom anti-VEGF therapeutics market Insights
The United Kingdom market reached approximately USD 0.75 billion in 2025. Increasing incidence of retinal diseases, an aging population, established ophthalmology services, and growing adoption of innovative anti-VEGF therapies are contributing to market expansion.
Asia-Pacific Anti-VEGF Therapeutics market Analysis
Asia-Pacific accounted for 21.4% of the global anti-VEGF therapeutics market, reaching USD 3.17 billion in 2025, and is projected to grow at the fastest regional CAGR of 9.4% during the forecast period. Rising healthcare expenditure, increasing prevalence of diabetes and retinal disorders, improving healthcare infrastructure, and growing access to advanced biologic treatments are supporting regional growth. Expanding pharmaceutical capabilities and increasing awareness of advanced ophthalmic therapies are also creating opportunities for market development.
Japan anti-VEGF therapeutics market Insights
Japan's market generated approximately USD 0.67 billion in 2025. Advanced healthcare infrastructure, a growing elderly population, high prevalence of age-related retinal conditions, and strong adoption of innovative ophthalmic treatments are supporting demand for anti-VEGF therapeutics.
China anti-VEGF therapeutics market Insights
China's market accounted for approximately USD 1.55 billion in 2025, making it a major contributor within the Asia-Pacific region. Expanding healthcare infrastructure, rising healthcare expenditure, increasing prevalence of diabetes and retinal diseases, and improving access to advanced biologic therapies are supporting market growth.
Latin America Anti-VEGF Therapeutics market Analysis
Latin America accounted for 5.1% of the global anti-VEGF therapeutics market in 2025, reaching USD 0.75 billion, and is projected to grow at a CAGR of 7.9% during the forecast period. Increasing healthcare investment, rising prevalence of diabetes and retinal disorders, improving access to specialized ophthalmic care, and growing awareness of advanced treatment options are supporting regional market development.
Brazil anti-VEGF therapeutics market Insights
Brazil's market was valued at approximately USD 0.75 billion in 2025. Increasing prevalence of retinal disorders, expansion of healthcare services, improving access to ophthalmic treatments, and growing adoption of advanced biologic therapies are supporting market development.
Middle East & Africa Anti-VEGF Therapeutics market Analysis
Middle East & Africa accounted for 3.7% of the global anti-VEGF therapeutics market in 2025, reaching USD 0.55 billion, and is expected to grow at a CAGR of 7.1% during the forecast period. Increasing healthcare infrastructure investment, rising prevalence of diabetes-related eye diseases, healthcare modernization, and improving access to specialized treatments are supporting regional growth. Growing awareness of advanced ophthalmic therapies is also contributing to increased adoption.
UAE anti-VEGF therapeutics market Insights
The UAE market was valued at approximately USD 0.19 billion in 2025. Healthcare infrastructure development, increasing investment in advanced medical technologies, rising prevalence of ophthalmic disorders, and growing access to specialized eye-care services are supporting the adoption of anti-VEGF therapeutics.
Anti-VEGF Therapeutics Market Competitive Landscape
The global Anti-VEGF Therapeutics market is highly competitive, driven by the rising prevalence of retinal disorders, increasing demand for targeted therapies, and continued development of treatments for conditions such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Key players include Regeneron Pharmaceuticals, Inc., Bayer AG, Novartis AG, F. Hoffmann-La Roche Ltd., Fresenius Kabi, Biogen, Pfizer, Inc., Alvotech, Teva Pharmaceuticals, Coherus Biosciences, Inc., Amgen, Inc., Bausch Health Companies, Inc., Viatris, Inc., Sanofi, Isarna Therapeutics, Genentech, SamChunDang Pharm, Formycon AG, and Bioeq AG. Companies are focusing on novel biologics, biosimilars, longer-acting therapies, improved drug delivery, and expanded treatment options to strengthen their market position.
Regeneron Pharmaceuticals, Inc.: An Emerging Market Leader
Regeneron has strengthened its position through its ophthalmology portfolio, including anti-VEGF therapies used to treat several retinal diseases. The company focuses on innovative biologic therapies, improved treatment outcomes, and research aimed at addressing a broad range of retinal conditions. These capabilities support Regeneron's strong position in the global anti-VEGF therapeutics market.
List of Key and Emerging Players in Anti-VEGF Therapeutics Market
Regeneron Pharmaceuticals, Inc.
Bayer AG
Novartis AG
Hoffmann-La Roche Ltd.
Frensius Kabi
Biogen
Pfizer, Inc.
Alvotech
Teva Pharmaceuticals
Coherus Biosciences, Inc.
Amgen, Inc.
Bausch Health Companies, Inc.
Viatris, Inc.
Sanofi
Isarna Therapeutics
Genentech
SamChunDang Pharm
Roche
Formycon AG
Bioeq AG
Key Industry Developments
June 2026: Regeneron Pharmaceuticals expanded its ophthalmology therapeutics portfolio by advancing next-generation anti-VEGF treatments designed for retinal diseases, including age-related macular degeneration and diabetic eye disorders. The company focused on improving treatment durability, reducing dosing frequency, and enhancing patient outcomes through innovative biologic therapies.
April 2026: Roche expanded its ophthalmology portfolio by advancing anti-VEGF therapeutic solutions featuring longer-acting formulations and improved delivery approaches for retinal conditions. The company focused on developing treatments that provide sustained disease control and improve convenience for patients requiring repeated injections.
January 2026: Novartis expanded its retinal disease treatment portfolio by strengthening its anti-VEGF therapy development programs focused on improving efficacy, extending treatment intervals, and supporting personalized approaches for patients with retinal vascular disorders.
October 2025: Bayer expanded its ophthalmology portfolio by advancing anti-VEGF treatment solutions for retinal diseases. The company focused on improving therapeutic effectiveness, expanding patient access, and developing innovative approaches for vision preservation.
Report Scope
Comments
No comment